Search Results

Campus: Weill Cornell Medicine


Return to Cornell Startups

Acuamark Diagnostics, Inc.

Category: Digital Health
Campus: Weill Cornell Medicine
Incubator:

Acuamark Diagnostics is developing novel diagnostic tests to enable low-cost and accurate early detection of colorectal cancer directly from the blood, by isolating and identifying multiple cancer markers. Thus, allowing for improved sensitivity, specificity, and scalability.

Location: New York, NY

Foundation Cornell Technology Licensed: 2014

AffyImmune Therapeutics

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018

Location: Natick, MA

Foundation Cornell Technology Licensed: 2017

Akelos, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.

Location: New York, New York

Foundation Cornell Technology Licensed: 2018

Angiocrine Bioscience, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Angiocrine Bioscience, Inc., is developing both research and therapeutic products using stem and endothelial cell related technologies.

Location: New York, NY

Foundation Cornell Technology Licensed: 2012

ArcScan, Inc

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator: Center for Life Science Ventures

ArcScan, Inc., is developing Artemis 3, a high-resolution ultrasound scanner that enables eye surgeons to design phakic and accommodative lenses to reduce the risk of bad outcomes in corneal surgeries and lens implants.

Location: Golden, CO

Foundation Cornell Technology Licensed: 2007

Aufbau Medical Innovations Ltd.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator: Center for Life Science Ventures

Aufbau Medical Innovations is an Irish Operating Company that develops novel therapeutics and diagnostics for ophthalmic diseases.

Location: Dublin, Ireland / Ithaca, NY

Foundation Cornell Technology Licensed: 2020

Big Blue Biotech

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Big Blue Biotech produces a novel catheter system designed to decrease the risk of contamination of urine specimens with peri-urethral bacteria when obtaining urine specimens from pediatric patients via bladder catheter.

Location: Westwood, Massachusetts

Foundation Cornell Technology Licensed: 2018

Bionic Sight, LLC

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Bionic Sight develops neuro-prosthetics—prosthetic devices to treat blindness due to retinal degenerative disease that interact with the nervous system in order to restore function to damaged or degenerated tissue in the eye. The company is developing a technique involving gene therapy and a wearable device that correctly transmits light pulses to the brain, giving the wearer sight.

Location: New York, NY

Foundation Cornell Technology Licensed: 2013

Biosleep

Category: Digital Health
Campus: Weill Cornell Medicine
Incubator:

Biosleep uses a proprietary algorithm and cloud-based analytics to conveniently and accurately diagnose sleep apnea.  The economic impact of undiagnosed sleep apnea is roughly $150B per annum. Less than 20% of patients suffering with obstructive sleep apnea have been currently diagnosed.

Location: Forest Hills, New York

Foundation Cornell Technology Licensed: 2019

BlinkBio, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

BlinkBio, Inc. employs specialized Bioorthogonal chemistries for the delivery of next generation medicines for the treatment of cancer and other diseases. BlinkBio has optimized their proprietary chemistries into two types of novel linkers: one that allows the improved targeting of cytotoxic cancer medicines designed to rapidly kill cancer cells (so called Small Molecule Drug Conjugates (SMDCs) and Antibody Drug Conjugates (ADCs)); and the other that designs larger self-assembling therapeutics to target important cancer genes (such as MYC and p53) which exist inside cells and are not addressable using more traditional cancer therapeutics.

 

Location: Jupiter, FL

Foundation Cornell Technology Licensed: 2009

C2i Genomics

Category: Diagnostics
Campus: Weill Cornell Medicine
Incubator:

C2i Genomics helps doctors and patients fight cancer by providing doctors and patients with tumor burden information, starting with only a blood sample.  Its service, called C2, uses software that performs pattern recognition on data from whole-genome sequencing of the blood sample.  Physicians can use the service to monitor their patient’s response to treatment and detect treatment failure or disease recurrence well before they would do otherwise.  Physicians can also use the service to measure treatment response in clinical trials.

Location: New York, NY

Foundation Cornell Technology Licensed: 2020

Cleerly, Inc.

Category: Digital Health
Campus: Weill Cornell Medicine
Incubator:

Cleerly is devoted to generating predictive and diagnostic software products using machine learning on radiological image data. The machine learning strategy licensed from Cornell can make connections and inferences about health that a human brain would miss. Their first round of products will be aimed at assessing heart health and will provide a user friendly platform for doctors and patients to learn about their heart by exploiting the connections made using the machine learning strategy. The technology was developed in the Dalio Institute for Cardiovascular Imaging.

Location: Brooklyn, NY

Foundation Cornell Technology Licensed: 2017

Convergent Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University.

 

Location: New York

Foundation Cornell Technology Licensed: 2021

Faeth Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Faeth Therapeutics, Inc. is a data-driven, evidence-based healthcare company, with a mission to rethink the role of nutrition in the fight against cancer.

Location: San Francisco, CA

Foundation Cornell Technology Licensed: 2020

Fesarius Therapeutics, Inc.

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal, and other forms of trauma. The company joined the National Institutes of Health as part of its I-Corps @ NIH Winter 2020 Program in February 2020.

Location: New York, NY

Foundation Cornell Technology Licensed: 2016

Fitzroy Salute, LLC

Category: Software
Campus: Weill Cornell Medicine
Incubator:

Fitzroy Salute, LLC offers an affordable and comprehensive environmental health and safety information management solution to streamline and improve EHS operations. The cloud-based IMS provides environmental health and safety staff with integrated modules for hazard assessment, safety and compliance, metric tracking, and more. Fitzroy Salute, LLC provides academic and healthcare institutions the tools they need to foster a true culture of safety, rather than just compliance.

Location: New York, NY

Foundation Cornell Technology Licensed: 2016

Guard Medical

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Guard Medical, a privately-held company, is developing easy-to-use and cost-effective solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with New York – Presbyterian and Weill Cornell Medicine in response to physicians’ identification of unmet needs related to Surgical Site Infections (SSI). Its investors include Bpifrance and Matignon Investissement et Gestion. Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.

 

Location: Paris, France

Foundation Cornell Technology Licensed: 2018

Hemogenyx Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BM”) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.

Location: Buffalo, NY

Foundation Cornell Technology Licensed: 2014

Immunovent, LLC

Category: Diagnostics
Campus: Weill Cornell Medicine
Incubator:

Immunovent, LLC is focused on the commercialization of next-generation technologies for allergy diagnosis. The company is developing the Local Allergy Mucosal Brush Test (LAMB-Dx), the first quantitative allergy diagnostic that will enable physicians to accurately test for both airborne and food allergies precisely where the clinical symptoms are occurring – in the mouth and nose.

Location: New York, NY

Foundation Cornell Technology Licensed: 2014

IpiNovyx Bio Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune and inflammatory are treated through a reversable, ultra-potent and non-toxic approach.

Location: West Nyack, NY

Foundation Cornell Technology Licensed: 2021

Larkspur Biosciences, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Location: Boston, MA

Foundation Cornell Technology Licensed: 2021

LEXEO Therapeutics, LLC

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.

Location: New York, NY

Foundation Cornell Technology Licensed: 2020

Lucerna, Inc.

Category: Biotech Research & Production Tools
Campus: Weill Cornell Medicine
Incubator:

Lucerna, Inc., is a biotechnology research company focused on developing and commercializing nucleic-acid based fluorescent sensors for Point-of-Care therapeutic diagnostics and environmental biomonitoring. Lucerna also offers newly developed antibodies for proteomic research.

Location: New York, NY

Foundation Cornell Technology Licensed: 2010

Lumendi Ltd.

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Lumendi Ltd., is focused on the development of new minimal invasive surgical tools and devices that will provide solutions for minimally invasive gastrointestinal surgeries. The company’s first product is an add-on to any commercially available endoscope that will avoid invasive colon resections to treat more complex gastrointestinal diseases.

Location: Buckinghamshire, England

Foundation Cornell Technology Licensed: 2014

Lumidyne Technologies, LLC

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Lumidyne develops next-generation fluorescent probes exhibiting superior brightness and stability compared with current commercially available reagents.

Location: New York, NY

Foundation Cornell Technology Licensed: 2014

MedimageMetric, LLC

Category: Digital Health
Campus: Weill Cornell Medicine
Incubator:

MedimageMetric, LLC, is developing and commercializing software for measuring organs and tissues from medical images for the Chinese market.

Location: New York, NY

Foundation Cornell Technology Licensed: 2010

Metro Mid-Atlantic Biotech, LLC

Category: Drug Discovery
Campus: Weill Cornell Medicine
Incubator:

Metro Mid-Atlantic Biotech is a development stage startup focused on developing novel small molecule therapeutics based on discoveries in the molecular mechanisms of aging and longevity in mammalian cells.

Location: Birmingham, MI

Foundation Cornell Technology Licensed: 2014

NeuroMedica, Inc.

Category: Diagnostics
Campus: Weill Cornell Medicine
Incubator:

NeuroMedica is developing a revolutionary endovascular flow diverter and coil-containment device for the minimally invasive treatment of bifurcation aneurysms.

Location: Johns Island, SC

Foundation Cornell Technology Licensed: 2018

Novita Pharmaceuticals, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.

Location: New York, NY

Foundation Cornell Technology Licensed: 2010

Onasys Controls

Category: Software
Campus: Weill Cornell Medicine
Incubator:

Export control for shipping research and clinical materials is complex and fraught with human error. Onasys leverages industry best practice and regulations to ensure your organization is productive, compliant, and safe. Onasys was founded by industry experts at Weill Cornell Medicine and Fitzroy Health.

Location: New York, NY

Foundation Cornell Technology Licensed: 2022

One Three BioTech

Category: Drug Discovery
Campus: Weill Cornell Medicine
Incubator:

OneThree Biotech is a VC backed startup developing a biology-driven Artificial Intelligence Technology Platform to accelerate drug discovery and development. The company’s platform enables the healthcare and pharmaceutical industry to quickly and accurately generate new testable insights and hypotheses by combing the world of systems and disease biology with computational tools to discover new treatments for patients in need. The platform helps identify novel targets, compounds and new drug combinations, as well as optimizes compounds for toxicity or efficacy.

Location: New York, NY

Foundation Cornell Technology Licensed: 2020

Pelex, Inc.

Category: Medical / Diagnostics Instrumentations
Campus: Weill Cornell Medicine
Incubator:

Pelex is a digital health platform for pelvic floor disorders built on a proprietary connected medical device. The goal of the company is to revolutionize the patient experience by bringing diagnosis AND treatment of pelvic floor disorders out of the clinic and into the home.

Location: New York, NY

Foundation Cornell Technology Licensed: 2019

RadRite

Category: Digital Health
Campus: Weill Cornell Medicine
Incubator:

Radrite is a non-profit, modern software company that has created the first mobile app for radiology CDSM. This software is inexpensive and easy for clinicians to integrate into their current practice.

Location: New York, NY

Foundation Cornell Technology Licensed: 2021

Ratio Therapeutics

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.

Location: New York, NY

Foundation Cornell Technology Licensed: 2021

Repairogen, Inc.

Category: Personal Products / Cosmetics
Campus: Weill Cornell Medicine
Incubator:

Repairogen is developing new compounds that reduce UV-induced skin damage, reduce skin aging and reduce the development of skin cancer.

Location: Ithaca, NY

Foundation Cornell Technology Licensed: 2013

Ship of Theseus LLC

Category: Biotech Research & Production Tools
Campus: Weill Cornell Medicine
Incubator:

Location:

Foundation Cornell Technology Licensed: 2020

Stealth BioTherapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Stealth BioTherapeutics, Inc., is a clinical stage, biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal and metabolic diseases. The company’s first clinical candidate, Bendaviaâ„¢, targets the mitochondria to treat cardio-renal and microvascular impairments.

Location: Newton, MA

Foundation Cornell Technology Licensed: 2006

VoiceLove, LLC

Category: Device
Campus: Weill Cornell Medicine
Incubator:

Location: Scarsdale, NY

Foundation Cornell Technology Licensed: 2021

Volastra Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.  The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.

Location: New York, NY

Foundation Cornell Technology Licensed: 2019

XyloCor Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.

Location: New York, NY

Foundation Cornell Technology Licensed: 2015